文献速递鼻科

美泊利单抗治疗德国重度慢性鼻窦炎伴鼻息肉的多种心真实世界疗效

Multi-centric real-world effectiveness of mepolizumab in severe chronic rhinosinusitis with nasal polyps in Germany.
PubMed 文献 · Rhinology · 2025-01-01

这项回顾性多种心研究纳入德国8家三级转诊中心96例接受美泊利单抗治疗的重度慢性鼻窦炎伴鼻息肉患者,其中36.5%为女性,平均年龄54.1±14.3岁。在治疗启动或从其他生物制剂转换后6个月内,患者报告的症状控制、嗅觉和鼻息肉评分均显著改善。转换组的各项结局指标较基线变化较小,而合并哮喘提示治疗成功率更高。

要点

  • 治疗启动或转换后6个月内,患者报告结局、嗅觉和鼻息肉评分均显著改善
  • 转换组结局指标较基线的变化小于非转换组
  • 合并哮喘提示美泊利单抗治疗成功率更高

核心结论

  • 真实世界数据显示美泊利单抗对慢性鼻窦炎伴鼻息肉具有持续疗效,包括较大比例曾接受其他生物制剂治疗的患者。
  • 该研究为迄今最大的真实世界队列,反映了真实治疗和疾病情境,证实美泊利单抗在重度慢性鼻窦炎伴鼻息肉中具有广泛适应证。

研究设计与样本

  • 回顾性多种心研究,纳入德国8家三级转诊中心诊断为重度慢性鼻窦炎伴鼻息肉并接受美泊利单抗治疗的患者96例,其中女性36.5%,平均年龄54.1±14.3岁。
  • 数据从患者病历中回顾性收集,分析基线至最长30个月的患者报告症状控制、血清生物标志物、鼻息肉评分和嗅觉变化。
  • 纳入人群包括生物制剂初治患者和从其他生物制剂转换的患者。

主要发现

  • 治疗启动或从其他生物制剂转换为美泊利单抗后6个月内,患者报告结局指标、嗅觉和鼻息肉评分均显著改善。
  • 转换组结局指标较基线的变化小于非转换组。
  • 合并哮喘提示治疗成功率更高。
  • 疗效在最长30个月观察期内持续。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Within the last years, monoclonal antibodies (biologicals) have revolutionized the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and significantly improved symptom control in otherwise refractory cases. The effectiveness of the biological mepolizumab, an IL-5 receptor antibody, has not yet been investigated extensively. This multi-centric study assesses its impact on a large German patient cohort including biological naive and switched patients. METHODOLOGY: In this retrospective multi-centric study, patients with the diagnosis of severe CRSwNP treated with mepolizumab by German tertiary referral centers were included. Data were collected retrospectively from patient records. The change from baseline regarding patient reported symptom control, serum biomarkers, nasal polyp score (NPS), and sense of smell were analysed over a course of up to 30 months. RESULTS: 96 patients from 8 tertiary treatment centers were included, 36.5% female, with a mean age of 54.1±14.3 years. Patient reported outcome measures, smell, and NPS improved significantly within 6 months after treatment initiation or switch from a different biological to mepolizumab. Change from baseline in outcome parameters was smaller in the switch-group, whereas comorbid asthma indicated greater treatment success. CONCLUSIONS: Our real-world data show a sustained therapeutic effect of mepolizumab in CRSwNP, including a large proportion of patients who were previously treated with a different biological. This study is the largest real-world cohort to date depicting realistic treatment and disease situations, confirming a broad range of indication for mepolizumab in severe CRSwNP.

来源:Rhinology,查看原文。版权归原作者所有。

引用

  1. B Rhold F, Hagemann J, Klimek L, et al. Multi-centric real-world effectiveness of mepolizumab in severe chronic rhinosinusitis with nasal polyps in Germany. Rhinology. 2025. PMID: 40621839. doi:10.4193/Rhin25.104

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。